e-learning
resources
Berlin 2008
Sunday, 05.10.2008
Pulmonary hypertension I
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Oral combination therapy bosentan/sildenafil delays time to clinical worsening in comparison to bosentan monotherapy
W. Jacobs, A. Vonk Noordegraaf, A. Boonstra, P. E. Postmus (Amsterdam, Netherlands)
Source:
Annual Congress 2008 - Pulmonary hypertension I
Session:
Pulmonary hypertension I
Session type:
Thematic Poster Session
Number:
1003
Disease area:
Pulmonary vascular diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
W. Jacobs, A. Vonk Noordegraaf, A. Boonstra, P. E. Postmus (Amsterdam, Netherlands). Oral combination therapy bosentan/sildenafil delays time to clinical worsening in comparison to bosentan monotherapy. Eur Respir J 2008; 32: Suppl. 52, 1003
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Muscle energy techniques for COPD patients: Effects on pulmonary function and activities of daily living
Related content which might interest you:
Clinical efficacy of oral sildenafil therapy in the treatment of pulmonary hypertension
Source: Eur Respir J 2007; 30: Suppl. 51, 347s
Year: 2007
Long-term treatment with fluticasone propionate/formoterol fumarate (FLUT/FORM) combination therapy is well-tolerated and provides sustained effectiveness in paediatric patients with asthma
Source: Annual Congress 2011 - Treating childhood asthma
Year: 2011
Combination therapy with sotatercept analog RAP-011 is superior to sildenafil alone in severe experimental PAH and RAP-011 benefits persist after treatment cessation
Source: Virtual Congress 2020 – Updated assessment and treatment of pulmonary arterial hypertension
Year: 2020
Lack of clinically relevant differences between combination therapy and monotherapy in COPD
Source: Eur Respir J 2014; 43: 1204
Year: 2014
Lack of clinically relevant differences between combination therapy and monotherapy in COPD
Source: Eur Respir J 2014; 43: 1204-1205
Year: 2014
One-year pulmonary safety and efficacy of inhaled insulin as adjunctive therapy in type 2 diabetes patients poorly controlled on oral agent monotherapy
Source: Eur Respir J 2004; 24: Suppl. 48, 618s
Year: 2004
Efficacy of oral add-on therapy in patients with pulmonary hypertension
Source: Annual Congress 2009 - Pulmonary hypertension
Year: 2009
Evaluating the efficacy of chronic therapy with tiotropium in COPD through discontinuation of treatment
Source: Eur Respir J 2002; 20: Suppl. 38, 245s
Year: 2002
Effect of once-daily tadalafil on exercise capacity and clinical deterioration with up to 68 weeks of treatment in patients with PAH
Source: Annual Congress 2009 - Pulmonary arterial hypertension
Year: 2009
Cost consequences of tiotropium plus existing therapy
versus
existing therapy alone following one year of treatment in patients with COPD
Source: Eur Respir J 2001; 18: Suppl. 33, 5s
Year: 2001
Efficacy of different dosing regimens of azithromycin in a real-world severe asthma cohort
Source: Virtual Congress 2021 – Advances in asthma treatment
Year: 2021
Short-term efficacy of advanced NSCLC patients receiving anlotinib hydrochloride as the first and second-line treatment
Source: Virtual Congress 2020 – Prognostic and predictive factors: treatment of lung cancer
Year: 2020
Fluticasone propionate/formoterol fumarate combination therapy has an efficacy and safety profile similar to that of its individual components administered concurrently in the treatment of asthma
Source: Annual Congress 2010 - Combination therapy in asthma and COPD
Year: 2010
Comparison of efficacy and safety of fixed-dose combination regimen versus separate drugs for treatment of tuberculosis
Source: International Congress 2019 – Insights into paediatric bronchology
Year: 2019
The efficacy, safety and tolerability of the short 12-month pre-XDR-TB regimen regimen in Ukraine at the expense of using intravenous administration of anti-tuberculosis drugs during intensive phase
Source: International Congress 2017 – Paediatric TB: MDRTB (II)
Year: 2017
Evaluation of efficacy and safety of budesonide/formeterol combination therapy in asthma patients
Source: Eur Respir J 2006; 28: Suppl. 50, 314s
Year: 2006
Budesonide/formoterol for maintenance and relief
vs.
higher dose ICS/LABA therapy: outcomes in patients symptomatic on high-dose inhaled corticosteroids (HDICS)
Source: Annual Congress 2007 - Recent advances in our understanding of the mechanisms of asthma treatment
Year: 2007
Comparison of efficacy and safety of twice-daily Glycopyrronium/Formoterol combination with once-daily Glycopyrronium in patients with moderate to severe COPD
Source: International Congress 2019 – COPD clinical trials: inhaled and oral therapies
Year: 2019
Safety profile of tiotropium add-on therapy in paediatric patients by gender
Source: International Congress 2018 – Innovative therapies in asthma and COPD
Year: 2018
Budesonide/formoterol reduces the use of oral corticosteroids in the treatment of COPD
Source: Eur Respir J 2003; 22: Suppl. 45, 50s
Year: 2003
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept